We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Case Report: Response to Almonertinib in a Patient With Metastatic NSCLC Resistant to Osimertinib due to Acquired EGFR L718Q Mutation.
- Authors
Shen, Gang; Shi, Lei; Tian, Xin; Huang, Depei; Chen, Hao; Gao, Chan; Shen, Xudong; Zhang, Hushan
- Abstract
Osimertinib shows strong clinical activity in first- and second-line treatment of nonsmall-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, especially EGFR T790M. However, when patients develop resistance, there is currently no definite postosimertinib treatment option. Herein, we report a patient with metastatic NSCLC who benefited from almonertinib after developing resistance to osimertinib.
- Subjects
EPIDERMAL growth factor receptors; OSIMERTINIB; NON-small-cell lung carcinoma
- Publication
Frontiers in Pharmacology, 2021, Vol 12, p1
- ISSN
1663-9812
- Publication type
Article
- DOI
10.3389/fphar.2021.731895